Spots Global Cancer Trial Database for ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIc Clinical Trial of ALA-PDT in Patients With Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in p16-positivity and High-risk HPV Infection
Study ID: NCT06439433
Study Description
Brief Summary: Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.
Detailed Description: A multi-center, randomized, double-blind, placebo-controlled phase IIc clinical trial of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Peking University Third Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
